National Board of Examinations

Question Paper Name :	DrNB CLINICAL HAEMATOLOGY Paper3
Subject Name :	DrNB CLINICAL HAEMATOLOGY Paper3
Creation Date :	2022-06-25 17:21:07
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB CLINICAL HAEMATOLOGY Paper3

Group Number :	1
Group Id :	3271871278
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB CLINICAL HAEMATOLOGY Paper3

Section Id :	3271871281
Section Number :	1

Mandatory or Optional :MandatoryNumber of Questions to be attempted :10Section Marks :100Enable Mark as Answered Mark for Review and Clear Response :PesMaximum Instruction Time :0Sub-Section Number :1Sub-Section Id :3271871285Question Shuffling Allowed :No	Section type :	Offline
Section Marks :100Enable Mark as Answered Mark for Review and Clear Response :YesMaximum Instruction Time :0Sub-Section Number :1Sub-Section Id :3271871285	Mandatory or Optional :	Mandatory
Enable Mark as Answered Mark for Review and Clear Response :YesMaximum Instruction Time :0Sub-Section Number :1Sub-Section Id :3271871285	Number of Questions to be attempted :	10
Clear Response :YesMaximum Instruction Time :0Sub-Section Number :1Sub-Section Id :3271871285	Section Marks :	100
Clear Response :0Maximum Instruction Time :0Sub-Section Number :1Sub-Section Id :3271871285	Enable Mark as Answered Mark for Review and	Voc
Sub-Section Number :1Sub-Section Id :3271871285	Clear Response :	165
Sub-Section Id : 3271871285	Maximum Instruction Time :	0
	Sub-Section Number :	1
Question Shuffling Allowed : No	Sub-Section Id :	3271871285
	Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718711832 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Chronic myeloid leukemia:

a) How do you choose first line therapy in CML-CP and why? [5]

b) Describe resistance mechanisms to TKI in CML. [5]

Question Number : 2 Question Id : 32718711833 Question Type : SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Hodgkin's Lymphoma:

a) Treatment of nodular lymphocyte predominant Hodgkin's lymphoma. [5]

b) Management of relapsed Hodgkin's lymphoma stage IA in a 45-year male after 10-years of ABVD therapy. [5]

Question Number : 3 Question Id : 32718711834 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Primary CNS Lymphoma:

a) Describe evaluation of a patient diagnosed with primary CNS lymphoma. [5]

b) Role of various treatment modalitites (chemotherapy, radiotherapy and autotransplant) in the treatment of primary CNS Lymphoma. [5]

Question Number : 4 Question Id : 32718711835 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Acute Myeloid Leukemia:

- a) Treatment of Acute Promyelocytic Leukemia. [5]
- b) Describe various conditioning regimens for AML. [5]

Question Number : 5 Question Id : 32718711836 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Hematological Complications in patients with COVID-19:

- a) Describe changes in various hematological parameters in patients with COVID-19. [5]
- b) Describe cytokine release syndrome in COVID-19 and role of Tocilizumab. [5]

Question Number : 6 Question Id : 32718711837 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

CART cells:

- a) Name the approved CART in diffuse large B cell lymphoma and their role vs autologous
- hematopoietic stem cell transplant in relapsed disease. [5]
- b) Describe complications of CART cell therapy and their management. [5]

Question Number : 7 Question Id : 32718711838 Question Type : SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time : 0

Hemophilia:

- a) How do you evaluate and manage chronic hemophilic arthropathy? [5]
- b) Newer treatment options in haemophilia therapy. [5]

Question Number : 8 Question Id : 32718711839 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Chronic Lymphocytic Leukemia (CLL):

- a) List various drugs and regimens used in the treatment of CLL. [5]
- b) Describe immune complication of CLL and their management. [5]

Question Number : 9 Question Id : 32718711840 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Myelodysplastic Syndrome (MDS):

- a) Risk-stratification of MDS. [3]
- b) Diagnosis and treament of childhood MDS. [4]
- c) Presentation and treatment of 5q MDS. [3]

Question Number : 10 Question Id : 32718711841 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Multiple Myeloma:

a) Diagnosis and management of monoclonal gammopathy of renal significance. [5]

b) Treatment of a 60-year male, relapsed multiple myeloma on lenalidomide maintenance after induction therapy with VRd and 18 months after autologous hematopoietic cell transplantation. [5]